Asia Pacific Continuous Glucose Monitoring Device (CGMD) Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sensors, Transmitters, and Receivers), Application (Type 1 Diabetes and Ty

The Asia Pacific Continuous Glucose Monitoring Device (CGMD) Market is poised for significant growth, with projections indicating a rise from US$ 2,944.6 million in 2024 to US$ 8,127.0 million by 2031, reflecting a compound annual growth rate (CAGR) of 15.8% from 2025 to 2031. This surge is primarily driven by the alarming increase in diabetes prevalence across the region, which is becoming a major public health concern.

As of 2024, approximately 1.4 billion adults aged 20-79 reside in the Asia Pacific, with over 320 million diagnosed with diabetes. This number is expected to escalate to 440 million by 2050, positioning Asia as the epicenter of the global diabetes epidemic. Notably, China and India account for more than half of the diabetes cases in the region, with China alone representing about 25% of the global adult diabetic population.

The rise in diabetes cases is largely attributed to urbanization, sedentary lifestyles, and dietary changes. For instance, a study in India revealed that 13.3% of adults aged 45-59 and 16.2% of those aged 60 and above are affected by diabetes, with actual prevalence likely higher than self-reported figures. Southeast Asia has also seen a dramatic increase in diabetes cases, from 34.9 million in 2000 to 106.9 million in 2024, with projections suggesting a rise to 185 million by 2050.

In response to this growing health crisis, companies are working to improve the availability and accessibility of CGM devices in the Asia Pacific region. Abbott Laboratories, for example, has launched the FreeStyle Libre and Lingo systems, which are available over-the-counter, thus eliminating the need for prescriptions. These devices have gained popularity in countries like Saudi Arabia and the UAE, where there is a high demand for effective diabetes management solutions.

The CGMD market is segmented by product, application, testing sites, and end users. In 2024, sensors dominated the product segment, while Type 2 diabetes accounted for the largest share in the application segment. Fingertip testing was the most common testing site, and self/homecare emerged as the leading end-user segment.

Continuous glucose monitoring devices offer significant advantages over traditional blood glucose monitoring methods. Unlike conventional approaches that rely on periodic finger-prick tests, CGMs provide real-time, continuous glucose level measurements through minimally invasive sensors. This allows users and healthcare providers to monitor glucose variability and trends rather than relying on isolated data points. Clinical studies have shown that CGM use can lead to reductions in HbA1c levels ranging from 0.25% to 3.0% and improve the percentage of time glucose remains within target levels by 15-34%, which is associated with a lower risk of diabetes complications and better long-term health outcomes.

One of the most notable features of CGM technology is its ability to provide real-time alerts for hypoglycemia and hyperglycemia. These alerts enable immediate interventions, such as consuming carbohydrates or adjusting insulin doses, significantly reducing the frequency and severity of dangerous episodes. Research indicates that low-glucose prediction algorithms in newer CGMs can decrease time spent below safe glucose levels by up to 92% compared to no alerts, enhancing safety, particularly during sleep or for high-risk patients.

CGMs also serve as powerful educational tools, encouraging personalized lifestyle changes by linking dietary intake, physical activity, medication responses, and stress factors to glucose fluctuations. This continuous feedback enhances self-management skills and patient engagement, offering insights that traditional education methods lack. The ongoing data stream allows for dynamic diabetes management, enabling patients and healthcare providers to make proactive, evidence-based decisions and adjust therapies between clinic visits.

In terms of country-specific insights, China is currently the largest market for CGM devices in the Asia Pacific region. The country faces a significant diabetes epidemic, with projections suggesting that by 2050, around 168 million individuals will be living with type 2 diabetes. This increase is driven by urbanization, dietary changes, and an aging population. The Chinese government has set ambitious goals to improve diabetes awareness and management, aiming for a 60% awareness rate among adults by 2030 and ensuring that 70% of type 2 diabetes patients receive standardized management services.

Key players in the CGMD market include Abbott Laboratories, Medtronic Plc, F. Hoffmann-La Roche Ltd, Tandem Diabetes Care Inc., Ypsomed Holding AG, Dexcom Inc., i-SENS Inc., Senseonics Holdings Inc., A. Menarini Diagnostics s.r.l., and Medtrum Technologies Inc. These companies are employing various strategies, including product innovation and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers. Show more